Rockefeller Capital Management’s Twist Bioscience TWST Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$535K Sell
11,253
-3,717
-25% -$167K ﹤0.01% 1943
2025
Q4
$475K Buy
14,970
+3,359
+29% +$105K ﹤0.01% 1936
2025
Q3
$327K Buy
+11,611
New +$352K ﹤0.01% 1974
2023
Q3
Sell
-10,144
Closed -$147K 1811
2023
Q2
$147K Sell
10,144
-844
-8% -$12.6K ﹤0.01% 1720
2023
Q1
$165K Buy
10,988
+6,099
+125% +$135K ﹤0.01% 1847
2022
Q4
$116K Sell
4,889
-22,255
-82% -$645K ﹤0.01% 1961
2022
Q3
$956K Buy
27,144
+1,684
+7% +$71.5K ﹤0.01% 1025
2022
Q2
$890K Buy
25,460
+2,059
+9% +$72.9K ﹤0.01% 1034
2022
Q1
$1.16M Buy
23,401
+1,980
+9% +$110K 0.01% 1002
2021
Q4
$1.66M Buy
21,421
+3,683
+21% +$378K 0.01% 872
2021
Q3
$1.9M Buy
17,738
+11,330
+177% +$1.3M 0.01% 772
2021
Q2
$853K Buy
6,408
+6,100
+1,981% +$709K ﹤0.01% 988
2021
Q1
$38K Sell
308
-562
-65% -$85.3K ﹤0.01% 2011
2020
Q4
$122K Buy
+870
New +$96.5K ﹤0.01% 1368

Other funds holding TWST

Rockefeller Capital Management's TWST Position: Q1 2026 in Review

Rockefeller Capital Management reduced its Twist Bioscience (TWST) stake by 25% in Q1 2026, selling an estimated $167K and leaving 11,253 shares worth $535K. The position accounts for ﹤0.01% of the portfolio, ranked #1943.

Rockefeller Capital Management first reported a position in TWST in Q4 2020 and has held it in 14 quarters since. The position peaked at $1.9M in Q3 2021. 279 funds tracked by Wall St. Rank hold TWST as of Q1 2026.

  • Rockefeller Capital Management held 11,253 shares of Twist Bioscience worth $535K as of Q1 2026.
  • Rockefeller Capital Management sold 3,717 Twist Bioscience shares in Q1 2026, an estimated $167K.
  • Twist Bioscience made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #1943 holding.
  • Rockefeller Capital Management first reported a position in Twist Bioscience in Q4 2020 and has held it in 14 quarters since.
  • Rockefeller Capital Management's Twist Bioscience position peaked at $1.9M in Q3 2021.
  • 279 funds tracked by Wall St. Rank held Twist Bioscience as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.